Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD

16.15  +0.05 (+0.31%)

After market: 16.15 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ADMA. ADMA was compared to 572 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, ADMA could be worth investigating further for value and growth investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in each of the past 5 years.
ADMA had negative operating cash flow in 4 of the past 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

ADMA has a Return On Assets of 17.44%. This is amongst the best in the industry. ADMA outperforms 98.23% of its industry peers.
ADMA's Return On Equity of 29.38% is amongst the best of the industry. ADMA outperforms 98.23% of its industry peers.
ADMA has a Return On Invested Capital of 26.25%. This is amongst the best in the industry. ADMA outperforms 99.47% of its industry peers.
Industry RankSector Rank
ROA 17.44%
ROE 29.38%
ROIC 26.25%
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin of ADMA (17.80%) is better than 96.64% of its industry peers.
Looking at the Operating Margin, with a value of 30.01%, ADMA belongs to the top of the industry, outperforming 98.58% of the companies in the same industry.
ADMA has a better Gross Margin (48.93%) than 77.70% of its industry peers.
Industry RankSector Rank
OM 30.01%
PM (TTM) 17.8%
GM 48.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ADMA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADMA has more shares outstanding
ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 15.67 indicates that ADMA is not in any danger for bankruptcy at the moment.
The Altman-Z score of ADMA (15.67) is better than 90.09% of its industry peers.
The Debt to FCF ratio of ADMA is 1.29, which is an excellent value as it means it would take ADMA, only 1.29 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ADMA (1.29) is better than 95.40% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that ADMA is not too dependend on debt financing.
The Debt to Equity ratio of ADMA (0.44) is worse than 73.81% of its industry peers.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 1.29
Altman-Z 15.67
ROIC/WACC2.41
WACC10.9%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

ADMA has a Current Ratio of 7.09. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADMA (7.09) is better than 67.79% of its industry peers.
A Quick Ratio of 3.26 indicates that ADMA has no problem at all paying its short term obligations.
The Quick ratio of ADMA (3.26) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 7.09
Quick Ratio 3.26
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

8

3. Growth

3.1 Past

ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 354.55%, which is quite impressive.
The Revenue has grown by 63.40% in the past year. This is a very strong growth!
The Revenue has been growing by 72.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%

3.2 Future

Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 68.48% on average per year.
The Revenue is expected to grow by 26.78% on average over the next years. This is a very strong growth
EPS Next Y502.12%
EPS Next 2Y177.63%
EPS Next 3Y113.19%
EPS Next 5Y68.48%
Revenue Next Year64.76%
Revenue Next 2Y36.9%
Revenue Next 3Y32.44%
Revenue Next 5Y26.78%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 57.68, the valuation of ADMA can be described as expensive.
Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 94.16% of the companies are valued more expensively.
ADMA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.51.
The Price/Forward Earnings ratio is 21.76, which indicates a rather expensive current valuation of ADMA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.51% of the companies listed in the same industry.
ADMA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 93.88.
Industry RankSector Rank
PE 57.68
Fwd PE 21.76
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.69% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 94.34% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 48.44
EV/EBITDA 31.03
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

ADMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADMA's earnings are expected to grow with 113.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y177.63%
EPS Next 3Y113.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADMA BIOLOGICS INC

NASDAQ:ADMA (1/31/2025, 4:41:09 PM)

After market: 16.15 0 (0%)

16.15

+0.05 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners78.63%
Inst Owner Change0.32%
Ins Owners2.27%
Ins Owner Change-1.86%
Market Cap3.82B
Analysts83.64
Price Target23.91 (48.05%)
Short Float %5.99%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.22%
Min EPS beat(2)13.12%
Max EPS beat(2)59.31%
EPS beat(4)3
Avg EPS beat(4)-74.67%
Min EPS beat(4)-413.72%
Max EPS beat(4)59.31%
EPS beat(8)6
Avg EPS beat(8)-6.12%
EPS beat(12)8
Avg EPS beat(12)-3.82%
EPS beat(16)11
Avg EPS beat(16)-2.62%
Revenue beat(2)2
Avg Revenue beat(2)16.3%
Min Revenue beat(2)10.99%
Max Revenue beat(2)21.61%
Revenue beat(4)4
Avg Revenue beat(4)9.23%
Min Revenue beat(4)0.42%
Max Revenue beat(4)21.61%
Revenue beat(8)8
Avg Revenue beat(8)7.55%
Revenue beat(12)12
Avg Revenue beat(12)8.5%
Revenue beat(16)16
Avg Revenue beat(16)8.17%
PT rev (1m)0%
PT rev (3m)23.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)47.62%
EPS NY rev (1m)0%
EPS NY rev (3m)4.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)16.25%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)4.13%
Valuation
Industry RankSector Rank
PE 57.68
Fwd PE 21.76
P/S 9.97
P/FCF 48.44
P/OCF 44.36
P/B 16.46
P/tB 16.75
EV/EBITDA 31.03
EPS(TTM)0.28
EY1.73%
EPS(NY)0.74
Fwd EY4.59%
FCF(TTM)0.33
FCFY2.06%
OCF(TTM)0.36
OCFY2.25%
SpS1.62
BVpS0.98
TBVpS0.96
PEG (NY)0.11
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.44%
ROE 29.38%
ROCE 33.23%
ROIC 26.25%
ROICexc 35.04%
ROICexgc 35.59%
OM 30.01%
PM (TTM) 17.8%
GM 48.93%
FCFM 20.59%
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 1.29
Debt/EBITDA 0.82
Cap/Depr 88.1%
Cap/Sales 1.89%
Interest Coverage 9.93
Cash Conversion 69.9%
Profit Quality 115.69%
Current Ratio 7.09
Quick Ratio 3.26
Altman-Z 15.67
F-Score8
WACC10.9%
ROIC/WACC2.41
Cap/Depr(3y)167.02%
Cap/Depr(5y)188.21%
Cap/Sales(3y)9.22%
Cap/Sales(5y)14.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
EPS Next Y502.12%
EPS Next 2Y177.63%
EPS Next 3Y113.19%
EPS Next 5Y68.48%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%
Revenue Next Year64.76%
Revenue Next 2Y36.9%
Revenue Next 3Y32.44%
Revenue Next 5Y26.78%
EBIT growth 1Y8410.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.64%
EBIT Next 3Y140.66%
EBIT Next 5Y89%
FCF growth 1Y179.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y200.53%
OCF growth 3YN/A
OCF growth 5YN/A